GlassScriptPhysician profile
Steven R Reeder
NPI 1295750057
$12,990.36
in general payments reported to CMS, 2019-2025
61 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,780 · 2020: $2,456 · 2021: $4,199 · 2022: $2,364 · 2023: $1,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,191.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,390.78 | 2020-2021 | |
| Abbvie INC. | $1,286.40 | 2019-2023 | |
| Novo Nordisk INC | $1,239.31 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $1,085.40 | 2019-2023 | Farxiga |
| Glaxosmithkline, LLC. | $990.86 | 2019-2023 | Trelegy Ellipta, Shingrix, Bexsero |
| Kowa Pharmaceuticals America, INC. | $906.86 | 2019-2023 | Seglentis, Livalo |
| Lilly USA, LLC | $692.14 | 2019-2023 | Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $511.73 | 2019-2022 | |
| Pfizer INC. | $481.88 | 2019-2023 | |
| Amarin Pharma, INC. | $434.01 | 2019-2021 | |
| Amgen INC. | $363.82 | 2019-2023 | Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $284.90 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $261.49 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $240.95 | 2019-2023 | Steglatro, Belsomra, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $239.88 | 2019-2021 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Reeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.